

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## AUSTRALIAN PRODUCT INFORMATION – ORSERDU® elacestrant (as dihydrochloride) tablets

### 1 NAME OF THE MEDICINE

Elacestrant dihydrochloride

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

#### ORSERDU 86 mg film coated tablets

Each film coated tablet contains elacestrant dihydrochloride equivalent to elacestrant 86.3 mg.

#### ORSERDU 345 mg film coated tablets

Each film coated tablet contains elacestrant dihydrochloride equivalent to elacestrant 345 mg.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

### 3 PHARMACEUTICAL FORM

#### ORSERDU 86 mg film coated tablets

Blue to light blue biconvex round shaped film coated tablet with ME debossed on one side and plain face on the opposite side. Approximate diameter: 8.8 mm.

#### ORSERDU 345 mg film coated tablets

Blue to light blue biconvex oval shaped film coated tablet with MH debossed on one side and plain face on the opposite side. Approximate size: 19.2 mm (length), 10.8 mm (width).

### 4 CLINICAL PARTICULARS

#### 4.1 THERAPEUTIC INDICATIONS

ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with an activating *ESR1* mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.

#### 4.2 DOSE AND METHOD OF ADMINISTRATION

Treatment with ORSERDU should be initiated by a physician experienced in the use of anticancer therapies.

Companion diagnostic (CDx) testing: For usage to be safe and effective, it is essential to select patients with ER-positive, HER2-negative advanced breast cancer for treatment with ORSERDU based on the presence of an activating *ESR1* mutation in tumour DNA (tDNA) in a plasma sample. Testing used in clinical practice should be adequately comparable to the testing used in the pivotal study.

#### Dosage

The recommended dose is 345 mg (one 345 mg film coated tablet), once daily.

The maximum recommended daily dose of ORSERDU is 345 mg.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

#### *Missed dose*

If a dose is missed, it can be taken immediately within 6 hours after the time it is usually taken. After more than 6 hours, the dose should be skipped for that day. On the next day, ORSERDU should be taken at the usual time.

#### *Vomiting*

If the patient vomits after taking the ORSERDU dose, the patient should not take an additional dose on that day and should resume the usual dosing schedule the next day at the usual time.

#### Dose modifications

The recommended elacestrant dose modifications for patients with adverse reactions (see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)) are provided in Tables 1 and 2.

**Table 1: ORSERDU dose reduction for adverse reactions**

ORSERDU dose level	Dose and schedule	Number and strength of tablets
Dose reduction	258 mg once daily	Three 86 mg tablets

If further dose reduction below 258 mg once daily is required, discontinue ORSERDU.

**Table 2: ORSERDU dose modification guidelines for adverse reactions**

Severity	Dose modification
Grade 2	Consider interruption of ORSERDU until recovery to Grade $\leq$ 1 or baseline. Then resume ORSERDU at the same dose level.
Grade 3	Interrupt ORSERDU until recovery to Grade $\leq$ 1 or baseline. The dose should be reduced to 258 mg when resuming therapy.  If the Grade 3 toxicity recurs, interrupt ORSERDU until recovery to Grade $\leq$ 1 or baseline. The reduced dose of 258 mg may be resumed at the discretion of the treating physician if the patient is benefiting from treatment. If a Grade 3 or intolerable adverse reaction recurs, permanently discontinue ORSERDU.
Grade 4	Interrupt ORSERDU until recovery to Grade $\leq$ 1 or baseline. The dose should be reduced to 258 mg when resuming therapy.  If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue ORSERDU.

#### *Use of ORSERDU with CYP3A4 inhibitors*

Concomitant use of strong or moderate CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered.

If a strong CYP3A4 inhibitor must be used, the elacestrant dose should be reduced to 86 mg once daily with careful monitoring of tolerability. If a moderate CYP3A4 inhibitor must be used, the elacestrant dose should be reduced to 172 mg once daily with careful monitoring of tolerability. Subsequent dose reduction to 86 mg once daily may be considered with moderate CYP3A4 inhibitors based on tolerability.

If the CYP3A4 inhibitor is discontinued, the elacestrant dose should be increased to the dose used prior to the initiation of the CYP3A4 inhibitor (after 5 half-lives of the CYP3A4 inhibitor) (see Sections 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS and 5.2 PHARMACOKINETIC PROPERTIES).

No dose adjustments are required for co-administration of ORSERDU with mild CYP3A4 inhibitors (see Section 4.5 Interactions With Other Medicines And Other Forms Of Interactions).

### *Use of ORSERDU with CYP3A4 inducers*

Concomitant use of strong or moderate CYP3A4 inducers should be avoided and an alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered.

If a strong or moderate CYP3A4 inducer must be used for a short duration of time (i.e.  $\leq 3$  days) or intermittently (i.e. treatment periods  $\leq 3$  days separated by at least 2 weeks or 1 week + 5 half-lives of the CYP3A4 inducer, whichever is longer), continue elacestrant without increasing the dose.

No dose adjustments are required for co-administration of ORSERDU with mild CYP3A4 inducers (see Sections 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS and 5.2 PHARMACOKINETIC PROPERTIES).

### Special populations

#### *Elderly*

No dose adjustment is required on the basis of patient age. Limited data are available in patients  $\geq 75$  years of age (see Section 5.2 PHARMACOKINETIC PROPERTIES).

#### *Hepatic impairment*

No dose adjustment is recommended for patients with mild hepatic impairment (*Child-Pugh A*). In patients with moderate hepatic impairment (*Child-Pugh B*), ORSERDU dose should be reduced to 258 mg. Elacestrant has not been studied in patients with severe hepatic impairment (*Child-Pugh C*), therefore no dose recommendation can be made for patients with severe hepatic impairment (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

#### *Renal impairment*

No dose adjustment in subjects with renal impairment is necessary. Elacestrant has not been studied in patients with severe renal impairment, therefore no dose recommendation can be made for patients with severe renal impairment (see Section 5.2 PHARMACOKINETIC PROPERTIES).

#### *Paediatric population*

The safety and efficacy of ORSERDU in children from birth to 18 years of age has not been established. No data are available.

### Method of administration

ORSERDU is for oral use.

The tablets should be swallowed whole. They should not be chewed, crushed or split prior to swallowing. Patients should take their dose of ORSERDU at approximately the same time each day. ORSERDU should be administered with a light meal. Administration with food may reduce nausea and vomiting (see Section 5.2 PHARMACOKINETIC PROPERTIES).

## **4.3 CONTRAINDICATIONS**

Hypersensitivity to elacestrant dihydrochloride or to any of the excipients listed in Section 6.1 LIST OF EXCIPIENTS.

### **SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

#### Use in hepatic impairment

ORSERDU is metabolised by the liver, and impaired hepatic function can increase the risk for adverse reactions. Therefore, ORSERDU should be used cautiously in patients with hepatic impairment and patients should be regularly and closely monitored for adverse reactions. Administration of elacestrant should be undertaken with caution at a dose of 258 mg once daily in patients with

moderate hepatic impairment (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION). In the absence of clinical data, elacestrant is not recommended in patients with severe hepatic impairment (*Child-Pugh C*) (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

#### Concomitant use with CYP3A4 inhibitors

Concomitant administration of ORSERDU with strong CYP3A4 inhibitors including, but not limited to: clarithromycin, itraconazole, ketoconazole, lopinavir/ritonavir, posaconazole, voriconazole and grapefruit or grapefruit juice should be avoided. An alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered. If the strong CYP3A4 inhibitor cannot be avoided, ORSERDU dose adjustment should be applied (see Sections 4.2 DOSE AND METHOD OF ADMINISTRATION and 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

Concomitant administration of ORSERDU with moderate CYP3A4 inhibitors including, but not limited to: aprepitant, ciprofloxacin, crizotinib, ciclosporin, diltiazem, erythromycin, fluconazole, fluvoxamine, grapefruit juice, imatinib, isavuconazole, and verapamil should be avoided. An alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered. If the moderate CYP3A4 inhibitor cannot be avoided, ORSERDU dose adjustment should be applied (see Sections 4.2 DOSE AND METHOD OF ADMINISTRATION and 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

#### Concomitant use with CYP3A4 inducers

Concomitant administration of ORSERDU with strong CYP3A4 inducers including, but not limited to: phenytoin, rifampicin, carbamazepine and St John's Wort (*Hypericum perforatum*) should be avoided. An alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered. If the strong CYP3A4 inducer cannot be avoided, ORSERDU dose adjustment should be applied (see Sections 4.2 DOSE AND METHOD OF ADMINISTRATION and 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

Concomitant administration of ORSERDU with moderate CYP3A4 inducers including, but not limited to: bosentan, dabrafenib, efavirenz, etravirine, lorlatinib, phenobarbital, primidone and sotorasib should be avoided. An alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered. If the moderate CYP3A4 inducer cannot be avoided, ORSERDU dose adjustment should be applied (see Sections 4.2 DOSE AND METHOD OF ADMINISTRATION and 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).

#### Thromboembolic events

Thromboembolic events are commonly observed in patients with advanced breast cancer and have been observed in clinical studies with ORSERDU (see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). This should be taken into consideration when prescribing ORSERDU to patients at risk.

#### Use in the elderly

No dosage adjustment is required on the basis of patient age (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

#### Paediatric use

The safety and efficacy of ORSERDU in children from birth to 18 years of age has not been established. No data are available.

#### Effects on laboratory tests

No data available.

## 4.4 Interactions with other medicines and other forms of interactions

Elacestrant is primarily metabolised by CYP3A4 and is a substrate of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1). Elacestrant is an inhibitor of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) efflux transporters.

### Effect of other medicinal products on ORSERDU

#### *CYP3A4 Inhibitors*

Co-administration of the strong CYP3A4 inhibitor itraconazole (200 mg once daily for 7 days) with ORSERDU (172 mg once daily for 7 days) increased elacestrant plasma exposure ( $AUC_{inf}$ ) and the peak concentration ( $C_{max}$ ) in healthy subjects 5.3 and 4.4-fold, respectively.

Physiologically based pharmacokinetic (PBPK) simulations in cancer patients suggested that the concomitant administration of multiple daily doses of elacestrant 345 mg and itraconazole 200 mg may increase elacestrant steady-state AUC and  $C_{max}$  5.5- and 3.9-fold, respectively, which may increase the risk of adverse reactions.

PBPK simulations in cancer patients suggested that concomitant administration of multiple daily doses of elacestrant 345 mg with moderate CYP3A4 inhibitors may increase elacestrant steady-state AUC and  $C_{max}$  by 2.3- and 1.9-folds, respectively, with fluconazole (200 mg once daily), and by 3.9- and 3.0-folds, respectively, with erythromycin (500 mg four times a day), which may increase the risk of adverse reaction.

#### *CYP3A4 Inducers*

Co-administration of the strong CYP3A4 inducer rifampicin (600 mg once daily for 7 days) with a single dose of ORSERDU 345 mg decreased elacestrant plasma exposure ( $AUC_{inf}$ ) and the peak concentration ( $C_{max}$ ) in healthy subjects by 86% and 73%, respectively, which may decrease elacestrant activity.

PBPK simulations in cancer patients suggested that the concomitant administration of multiple daily doses of elacestrant 345 mg and rifampicin 600 mg may decrease elacestrant steady-state AUC and  $C_{max}$  by 84% and 77%, respectively, which may decrease elacestrant activity.

PBPK simulations in cancer patients suggested that the concomitant administration of multiple daily doses of elacestrant 345 mg and the moderate CYP3A4 inducer efavirenz (600 mg) may decrease elacestrant steady-state AUC and  $C_{max}$  by 57% and 52%, respectively, which may decrease elacestrant activity.

#### *OATP2B1 inhibitors*

Elacestrant is a substrate of OATP2B1 *in vitro*. As it cannot be excluded that the co-administration of OATP2B1 inhibitors may increase the exposure of elacestrant, which may increase the risk of adverse reactions, caution is recommended in case of concomitant use of ORSERDU with OATP2B1 inhibitors.

### Effect of ORSERDU on other medicinal products

#### *P-gp substrates*

Co-administration of ORSERDU (345 mg, single dose) with digoxin (0.5 mg, single dose) increased digoxin exposure by 27% for  $C_{max}$  and 13% for AUC. Digoxin administration should be monitored and its dose reduced as necessary.

Concomitant use of ORSERDU with other P-gp substrates may increase their concentrations, which may increase the adverse reactions associated with the P-gp substrates. The dose of co-administered P-gp substrates should be reduced according to their Product Information.

#### *BCRP substrates*

Co-administration of ORSERDU (345 mg, single dose) with rosuvastatin (20 mg, single dose) increased rosuvastatin exposure by 45% for  $C_{max}$  and 23% for AUC. Rosuvastatin administration should be monitored and its dose reduced as necessary.

Concomitant use of ORSERDU with other BCRP substrates may increase their concentrations, which may increase the adverse reactions associated with the BCRP substrates. The dose of co-administered BCRP substrates should be reduced according to their Product Information.

## 4.5 FERTILITY, PREGNANCY AND LACTATION

### Effects on fertility

Fertility studies in animals have not been conducted. Based on findings from repeated-dose toxicity studies in animals and its mechanism of action, ORSERDU may impair fertility in females and males of reproductive potential. In repeated-dose toxicity studies effects related to fertility were observed in rat and monkey female reproductive tract (enlarged ovary, hyperplasia, decreased corpora lutea, ovarian cysts, atrophy of the vagina, cervix and uterus); these effects occurred at oral doses  $\geq 10$  mg/kg/day in rats and monkeys resulting in exposures (AUC) below human exposures at MRHD (maximum recommended human dose). Decreased cellularity of Leydig cells in rat testes was also observed at oral doses of 50 mg/kg/day resulting in exposures (AUC) 2.7-fold higher than in humans at the MRHD.

### Women of childbearing potential/Contraception in males and females

ORSERDU should not be used during pregnancy or in women of childbearing potential not using contraception. Based on the mechanism of action of elacestrant and findings from reproductive toxicity studies in animals, ORSERDU can cause fetal harm when administered to pregnant women. Females of reproductive potential should be advised to use effective contraception during treatment with ORSERDU and one week after the last dose.

### Use in pregnancy

#### PREGNANCY CATEGORY D

There are no data from the use of elacestrant in pregnant women. Studies in animals have shown reproductive toxicity. In an embryofetal development study in rats, oral administration of elacestrant resulted in maternal toxicity (body weight loss, low food consumption, red vulvar discharge) and embryofetal death (increased resorptions and post-implantation loss and reduced number of live fetuses) at  $\geq 3$  mg/kg/day. Additional adverse effects include lower fetal weights and malformations of the skull and limbs at  $\geq 10$  mg/kg/day. These effects occurred at exposure (AUC) below human exposures at the MHRD.

ORSERDU should not be used during pregnancy or in women of childbearing potential not using contraception. The pregnancy status of females of reproductive potential should be verified prior to starting treatment with ORSERDU. If pregnancy occurs while taking ORSERDU, the patient must be informed of the potential hazard to the fetus and potential risk of miscarriage.

### Use in lactation

It is unknown whether elacestrant/metabolites are excreted in human milk. Because of the potential for serious adverse reactions in the breast-fed infant, it is recommended that lactating women should not breast-feed during treatment with ORSERDU and one week after the last dose of ORSERDU.

## 4.6 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

ORSERDU has no or negligible influence on the ability to drive and use machines. However, since fatigue, asthenia, and insomnia have been reported in some patients taking elacestrant (see Section 4.7 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)), caution should be observed by patients who experience those adverse reactions when driving or operating machinery.

## 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

### Summary of the safety profile

The most common ( $\geq 10\%$ ) adverse reactions with ORSERDU were nausea, triglycerides increased, cholesterol increased, vomiting, fatigue, dyspepsia, diarrhoea, calcium decreased, back pain, creatinine increased, arthralgia, sodium decreased, constipation, headache, hot flush, abdominal pain, anaemia, potassium decreased, and alanine aminotransferase increased. The most common Grade  $\geq 3$  ( $\geq 2\%$ ) adverse reactions of elacestrant were nausea (2.7%), AST increased (2.7%), ALT increased (2.3%), anaemia (2%), back pain (2%), and bone pain (2%).

Serious adverse reactions reported in  $\geq 1\%$  of patients included nausea, dyspnoea, and thromboembolism (venous).

Adverse reactions leading to discontinuation in  $\geq 1\%$  of patients included nausea and decreased appetite.

Adverse reactions leading to dose reduction in  $\geq 1\%$  of patients included nausea.

Adverse reactions leading to dose interruption in  $\geq 1\%$  of patients were nausea, abdominal pain, alanine aminotransferase increased, vomiting, rash, bone pain, decreased appetite, aspartate aminotransferase increased, and diarrhoea.

### Tabulated list of adverse reactions

Adverse reactions described in the list below reflect exposure to elacestrant in 301 patients with breast cancer in three open label studies (RAD1901-005, RAD1901-106, and RAD1901-308) in which patients received elacestrant 400 mg once daily as a single agent. The frequencies of adverse reactions are based on all-cause adverse event frequencies identified in patients exposed to elacestrant at the recommended dose in the target indication, whereas frequencies for changes in laboratory parameters are based on worsening from baseline by at least 1 grade and shifts to  $\geq$  grade 3. The median duration of treatment was 85 days (range 5 to 1288).

The adverse reaction frequencies from clinical trials are based on all-cause adverse event frequencies, where a proportion of the events for an adverse reaction may have other causes than the drug, such as the disease, other medication or unrelated causes.

The following convention is used for the classification of the frequency of an adverse drug reaction (ADR) and is based on the Council for International Organizations of Medical Sciences (CIOMS) guidelines: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1\ 000$  to  $< 1/100$ ); rare ( $\geq 1/10\ 000$  to  $< 1/1\ 000$ ); very rare ( $< 1/10\ 000$ ); not known (cannot be estimated from the available data).

**Table 3: Adverse reactions in patients treated with elacestrant monotherapy 345 mg in metastatic breast cancer**

	<b>Elacestrant N= 301</b>	
<b>Infections and infestations</b>	Common	Urinary tract infection
<b>Blood and lymphatic system disorders</b>	Very common	Anaemia
	Common	Lymphocyte count decreased
<b>Metabolism and nutrition disorders</b>	Very common	Decreased appetite
<b>Psychiatric disorders</b>	Common	Insomnia
<b>Nervous system disorder</b>	Very common	Headache
	Common	Dizziness, Syncope
<b>Vascular disorders</b>	Very common	Hot flush*
	Uncommon	Thromboembolism (venous)*
<b>Respiratory, thoracic and mediastinal disorders</b>	Common	Dyspnoea, Cough*
<b>Gastrointestinal disorders</b>	Very common	Nausea, Vomiting, Diarrhoea, Constipation, Abdominal pain*, Dyspepsia*

	<b>Elacestrant N= 301</b>	
	Common	Stomatitis
<b>Hepatobiliary disorders</b>	Uncommon	Acute hepatic failure
<b>Skin and subcutaneous tissue disorders</b>	Common	Rash*
<b>Musculoskeletal and connective tissues disorders</b>	Very common	Arthralgia, Back pain
	Common	Pain in extremity, Musculoskeletal chest pain*, Bone pain
<b>General disorders and administration site conditions</b>	Very common	Fatigue
	Common	Asthenia
<b>Investigations</b>	Very common	Aspartate aminotransferase increased, Triglycerides increased, Cholesterol increased, Alanine aminotransferase increased, Calcium decreased, Creatinine increased, Sodium decreased, Potassium decreased
	Common	Blood alkaline phosphatase increased

\*Incidence represents a grouping of similar terms.

ADRs listed by system organ class and by decreasing frequency.

#### Description of selected adverse reactions

##### *Nausea*

Nausea was reported in 35% of patients. Grade 3-4 nausea events were reported in 2.5% of patients. Nausea was generally reported early, with a median time to the first onset 14 days (range: 1 to 490 days). Nausea occurred more frequently in the first cycle and from Cycle 2 onward, the incidence of nausea was generally lower in subsequent cycles (i.e., over time). Prophylactic treatment for nausea was prescribed for 12 (5%) subjects in the elacestrant arm and 28 (11.8%) received an antiemetic for the treatment of nausea during the on-treatment period.

##### *Elderly*

In the RAD1901-308 study, 104 patients who received elacestrant were ≥ 65 years and 40 patients were ≥ 75 years. Gastrointestinal disorders were reported more frequently in patients aged ≥ 75 years. Monitoring of treatment emergent adverse reactions by the treating physician, should include consideration of the patient's age and comorbidities, when selecting personalised interventions.

#### Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Health professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>.

## **4.9 OVERDOSE**

The highest dose of ORSERDU administered in clinical studies was 1000 mg per day. The adverse drug reactions reported in association with doses higher than the recommended dose were consistent with the established safety profile (see Section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)). The frequency and severity of gastrointestinal disorders (abdominal pain, nausea, dyspepsia and vomiting) appeared to be dose-related. There is no known antidote for an overdose of ORSERDU. Patients should be closely monitored and treatment of overdose should consist of supportive treatment.

For information on the management of overdose, contact the Poison Information Centre on 13 11 26 (Australia).

## **5 PHARMACOLOGICAL PROPERTIES**

## 5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Endocrine therapy, anti-estrogen, ATC code: L02BA04

### Mechanism of action

Elacestrant, a tetrahydronaphthalene compound, is an orally active estrogen receptor- $\alpha$  (ER $\alpha$ ) antagonist and degrader.

### Pharmacodynamic effects

Elacestrant inhibits the estradiol-dependent and independent growth of ER $\alpha$ -positive breast cancer cells, including models harbouring estrogen receptor 1 (*ESR1*) gene mutations in the ligand binding domain. Elacestrant displayed antitumour activity in patient derived xenograft models previously exposed to multiple endocrine therapies, harbouring wild type *ESR1* or *ESR1* gene mutations in the ligand binding domain.

In patients with ER+ advanced breast cancer with a median of 2.5 prior lines of endocrine therapy, dosed with elacestrant dihydrochloride 400 mg (345 mg of elacestrant) daily, median reduction in tumour  $16\alpha$ - $18F$ -fluoro- $17\beta$ -estradiol (FES) uptake from baseline to Day 14 was 88.7% demonstrating reduced ER availability and antitumour activity measured by FES-PET/CT in patients with prior endocrine therapies.

### Clinical trials

The efficacy and safety of ORSERDU in patients with ER+/HER2- advanced breast cancer following prior endocrine therapy in combination with a CDK4/6 inhibitor was evaluated in RAD1901-308, a randomised, open-label, active-controlled, multicentre trial which compared ORSERDU with standard of care (SOC) (fulvestrant for patients who received prior aromatase inhibitors in the metastatic setting or aromatase inhibitors for patients who received fulvestrant in the metastatic setting). Eligible patients included post-menopausal women and men whose disease had relapsed or progressed on at least 1 and no more than 2 prior lines of endocrine therapy. All patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and evaluable lesions per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, i.e. measurable disease or bone only disease with evaluable lesions. Prior endocrine therapy must have included a combination with CDK4/6 inhibitor therapy and no more than 1 prior line of cytotoxic chemotherapy for metastatic breast cancer. Patients were required to be appropriate candidates for endocrine monotherapy. Patients with presence of symptomatic metastatic visceral disease, patients with cardiac comorbidity, and patients with severe hepatic impairment were excluded.

A total of 478 patients were randomised 1:1 to daily oral administration of 400 mg of elacestrant dihydrochloride (345 mg of elacestrant) or standard of care (SOC) (239 on elacestrant and 239 on SOC), including a total of 228 patients (47.7%) with *ESR1* mutations at baseline (115 patients on elacestrant and 113 patients on SOC). Among the 239 patients randomised to the SOC arm, 166 received fulvestrant, and 73 received an aromatase inhibitor that included anastrozole, letrozole or exemestane. Randomisation was stratified by *ESR1* mutations status (*ESR1*-mut vs *ESR1*-mut-nd [no *ESR1* mutations detected]), prior treatment with fulvestrant (yes vs no), and visceral metastasis (yes vs no). *ESR1* mutational status was determined by blood circulating tumour deoxyribonucleic acid (ctDNA) using the Guardant360 CDx assay and was limited to *ESR1* missense mutations in the ligand binding domain (between codons 310 to 547).

The median age of patients (ORSERDU vs standard of care) at baseline was 63.0 years (range of 24-89) vs 63.0 (range of 32-83) and 45.0% were over 65 (43.5 vs 46.4). Most patients were women (97.5% vs 99.6%) and most patients were white (88.4% vs 87.2%), followed by Asian (8.4% vs 8.2%), Black or African American (2.6% vs 4.1%), and Other/Unknown (0.5% vs 0.5%). Baseline ECOG performance status was 0 (59.8% vs 56.5%), 1 (40.2% vs 43.1%) or > 1 (0% vs 0.4%). Patient demographics for those with *ESR1*-mutated tumours were generally representative of the broader study population. The median duration of exposure to ORSERDU was 2.8 months (range: 0.4 to 24.8).

The primary efficacy endpoint was progression-free survival (PFS) as assessed by IRC (Independent Review Committee) in all patients, i.e., including patients with an *ESR1* mutation, and in patients with *ESR1* mutations. A statistically significant PFS benefit was observed in all patients with a median PFS of 2.79 months in the ORSERDU arm as compared with 1.91 months in the standard of care arm (HR= 0.70, 95% CI: 0.55, 0.88). Efficacy results are presented in Table 4 and Figure 1 for patients with *ESR1* mutations.

**Table 4: Efficacy results among patients with *ESR1* mutations (evaluated by a blinded imaging review committee)**

	ORSERDU	Standard of care
<b>Progression-free survival (PFS)</b>	<b>N = 115</b>	<b>N = 113</b>
Number of PFS events, n (%)	62 (53.9)	78 (69.0)
Median PFS months* (95% CI)	3.78 (2.17, 7.26)	1.87 (1.87, 2.14)
Hazard ratio** (95% CI)	0.546 (0.387, 0.768)	
p-value (stratified log-rank)	0.0005	
<b>Overall survival (OS)</b>	<b>N = 115</b>	<b>N = 113</b>
Number of OS events, n(%)	61 (53)	60 (53.1)
Median OS months* (95% CI)	24.18 (20.53, 28.71)	23.49 (15.64, 29.90)
Hazard ratio** (95% CI)	0.903 (0.629, 1.298)	


CI=confidence interval; *ESR1*=estrogen receptor 1; PFS=progression-free survival.

\* Kaplan-Meier estimate; 95% CI based on the Brookmeyer-Crowley method using a linear transformation.

\*\* From a Cox proportional hazards model stratified by prior treatment with fulvestrant (yes vs no), and visceral metastasis (yes vs no).

Data cut-off dates are 06 September 2021 for PFS and 02 September 2022 for OS.

**Figure 1: PFS in patients with an *ESR1* mutation (evaluated by a blinded imaging review committee)**



### Paediatric population

The safety and efficacy of ORSERDU in children from birth to 18 years of age has not been established. No data are available.

## 5.2 PHARMACOKINETIC PROPERTIES

The elacestrant oral bioavailability is approximately 10%. Steady state is reached by Day 6 following once daily dosing.  $C_{max}$  and AUC increase slightly more than proportional to dose for doses  $\geq 50$  mg (salt form).

## Absorption

Following oral administration, elacestrant was rapidly absorbed, reaching  $C_{max}$  within 1-4 hours. The geometric mean  $C_{max}$  was 52.86 ng/mL (35.2% coefficient of variation [CV%]) and  $AUC_{inf}$  was 1566 ng\*h/mL (38.4% CV) after single dose administration of 345 mg of elacestrant in fed conditions. At steady state, the median [min, max] plasma concentration at 4h post-dose ( $C_{4h}$ ) and AUC are predicted to be 108 ng/mL [27.5 – 351] and 2190 ng\*h/mL [461 – 8470], respectively.

### *Effect of food*

Administration of elacestrant 345 mg tablet with a high-fat high-calorie meal increased  $C_{max}$  and AUC by 40% and 20%, respectively, as compared to fasted administration. When the tablet was co-administered with a light meal,  $C_{max}$  and AUC increased in a similar fashion, i.e. by 30 and 20%, respectively. Ingestion with food may reduce gastrointestinal adverse effects.

## Distribution

Plasma protein binding of elacestrant is > 99% and independent of concentration and hepatic impairment status. Elacestrant penetrates the blood brain barrier in a dose-dependent manner. Following once daily administration of elacestrant for 7 consecutive days, median concentrations of elacestrant in the cerebrospinal fluid were 0.0966 ng/mL and 0.155 ng/mL at the doses of 200 and 500 mg, respectively.

Based on population pharmacokinetic analysis, elacestrant is extensively distributed in the tissues with an apparent peripheral volume of distribution of 5411 L. The apparent central volume of distribution of elacestrant at steady state is 422 L.

## Metabolism

Elacestrant was a minor (< 10% of plasma radioactivity) component in human plasma. 4-[2-(Ethylamino)ethyl]benzoic acid (EAEBA) glucuronide was a major human plasma metabolite (about 41% of plasma radioactivity). Elacestrant is primarily metabolised by CYP3A4 with a potential small contribution by CYP2A6 and CYP2C9.

## Excretion

The half-life of elacestrant is predicted to be approximately 30 hours. After a single dose, the mean (% CV) clearance of elacestrant was 220.3 L/hr (38.4%). At steady state, the mean (% CV) clearance of elacestrant is predicted to be 186 L/hr (43.5%).

Following a single oral dose of 345 mg radiolabelled elacestrant, 81.5% (majority as unchanged) was recovered in faeces and 7.53% (trace as unchanged) was recovered in urine. Elacestrant renal clearance is very low ( $\leq 2.3$  mL/min) and it was eliminated by oxidative metabolism and faecal excretion.

## Special populations

### *Effect of age, weight and gender*

From analyses of population pharmacokinetic data in cancer patients, no dose adjustment is warranted based on body weight, age, and gender.

### *Hepatic impairment*

The  $C_{max}$  and AUC values were similar between subjects in the mild hepatic impairment group (*Child-Pugh A*) and the normal hepatic function group upon single dose administration of elacestrant 176 mg. There were significant increases in  $AUC_{0-t}$  (76%) and  $AUC_{0-\infty}$  (83%) in the moderate hepatic impairment group (*Child-Pugh B*) compared to the normal hepatic function group. The  $C_{max}$  values were similar between the normal and moderate impairment groups.

The geometric mean elimination half-life ( $t_{1/2}$ ) tended to increase with increasing severity of hepatic impairment. Elacestrant has not been studied in subjects with severe hepatic impairment (*Child-Pugh C*).

In PBPK modelling simulation of elacestrant at 345 mg, the steady state AUC and  $C_{max}$  were predicted to increase by 2.14- and 1.92-fold, respectively, in subjects with moderate hepatic impairment compared to patients with normal hepatic function.

## 5.3 PRECLINICAL SAFETY DATA

### Genotoxicity

Elacestrant showed no genotoxic potential in the Ames test, chromosomal aberrations in human lymphocytes and in the micronucleus assay in rats.

### Carcinogenicity

No data available.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 LIST OF EXCIPIENTS

#### Tablet core

Microcrystalline cellulose, silicified microcrystalline cellulose, crospovidone, magnesium stearate, and silica amorphous.

#### Film coating

Opadry II 85F105080 Blue (polyvinyl alcohol, titanium dioxide, macrogol 3350, purified talc and Brilliant Blue FCF Aluminium Lake).

### 6.2 INCOMPATIBILITIES

Not applicable.

### 6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### 6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

### 6.5 NATURE AND CONTENTS OF CONTAINER

ORSERDU is packaged in aluminium-aluminium blisters packed into a cardboard box.

#### ORSERDU 86 mg film coated tablets

Packs containing 28 film coated tablets: 4 blisters with 7 tablets each

#### ORSERDU 345 mg film coated tablets

Packs containing 28 film coated tablets: 4 blisters with 7 tablets each


### 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

## 6.7 PHYSIOCHEMICAL PROPERTIES

### Chemical structure

Elacestrant dihydrochloride is an estrogen receptor antagonist, and has the chemical name: (6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride.



Chiral center denoted by asterisk (\*)

Molecular formula: C<sub>30</sub>H<sub>40</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>

### CAS number

1349723-93-8

## 7 MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 (Prescription Only Medicine)

## 8 SPONSOR

A. Menarini Australia Pty Ltd  
Sydney, Australia  
Telephone: 1800 644 542

## 9 DATE OF FIRST APPROVAL

DAY MONTH YEAR

## 10 DATE OF REVISION

Not applicable – first version.

### Summary Table of Changes

Section changed	Summary of new information
Not applicable	Initial version